An evaluation of global coagulation assays in myeloproliferative neoplasm

Blood Coagulation and Fibrinolysis

Volumn 29, Issue 3, 2018, Pages 300-306

  Lim, Hui Y ^a,b,c   Ng, Cheryl ^a   Rigano, Joseph ^d   Tacey, Mark ^b   Donnan, Geoffrey ^c   Nandurkar, Harshal ^b   Ho, Prahlad ^a,b,c  

^a NORTHERN HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d AUSTIN HEALTH   (Australia)

Author keywords

coagulation assays; essential thrombocythaemia; myeloproliferative neoplasm; polycythaemia vera; thromboelastography; thrombosis

Indexed keywords

FIBRIN; PADGEM PROTEIN; THROMBIN;

ADULT; AGED; ARTICLE; ASSAY; BLOOD CELL COUNT; BLOOD SAMPLING; BONE MARROW BIOPSY; CANCER PATIENT; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GLOBAL COAGULATION ASSAY; HUMAN; LABORATORY TEST; MALE; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SURGICAL PATIENT; THROMBOCYTE POOR PLASMA; THROMBOCYTHEMIA; THROMBOELASTOGRAPHY; BIOSYNTHESIS; BLOOD; BLOOD CLOTTING TEST; CASE CONTROL STUDY; EVALUATION STUDY; MIDDLE AGED; MYELOPROLIFERATIVE DISORDER; NEOPLASM; PROGNOSIS; STANDARDS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; NEOPLASMS; PROGNOSIS; THROMBELASTOGRAPHY; THROMBIN;

EID: 85046788580     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000724     Document Type: Article

References (33)

1. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995; 123:656-664.
2. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23:2224-2232.
3. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117:755-761.
4. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007; 110:840-846.
5. Casini A, Fontana P, Lecompte TP. Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management. J Thromb Haemost 2013; 11:1215-1227.
6. Reikvam H, Tiu RV. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukaemia 2012; 26:563-571.
7. Lim HY, Ng C, Donnan G, Nandurkar H, Ho P. Ten years of cerebral venous thrombosis: male gender and myeloproliferative neoplasm is associated with thrombotic recurrence in unprovoked events. J Thromb Thrombolysis 2016; 42:423-431.
8. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350:114-124.
9. Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007; 109:2446-2452.
10. Palandri F, Polverelli N, Catani L, Ottaviani E, Baccarani M, Vianelli N. Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann Hematol 2011; 90:933-938.
11. Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Bü ller HR, CattaneoM. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res 2009; 124:409-417.
12. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukaemia 2007; 21:1952-1959.
13. Klampfl T, Gisslinger H, Harutyunan A, Nivarthi H, Rumi E, Milosevic J, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369:2379-2390.
14. Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, Cavalloni C, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukaemia 2016; 30:431-438.
15. Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol 2006; 19:617-633.
16. Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood 2017; 129:680-692.
17. Ho P, Ng C, Rigano J, Tacey M, Smith C, Donnan G, et al. Significant age, race and gender differences in global coagulation assays parameters in the normal population. Thromb Res 2017; 154:80-83.
18. Bowbrick VA, Mikhailidis DP, Stansby G. The use of citrated whole blood in thromboelastography. Anesth Analg 2000; 90:1086-1088.
19. Anderson L, Quasim I, Steven M, Moise SF, Shelley B, Schraag S, et al. Interoperator and intraoperator variability of whole blood coagulation assays: a comparison of thromboelastography and rotational thromboelastometry. J Cardiothorac Vasc Anesth 2014; 28:1550-1557.
20. Hemker HC, Al Dieri R, De Smedt E, Bé guin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006; 96:553-561.
21. Antovic A. The overall hemostasis potential: a laboratory tool for the investigation of global hemostasis. Semin Thromb Hemost 2010; 36: 772-779.
22. IBL International GMBH. sP-selectin ELISA (product information). 2014.
23. Trelin ski J, OkonskaM. Robak M, Chojnowski K. Assessment of rotation thromboelastometry parameters in patients with essential thrombocythemia at diagnosis and after hydroxyurea therapy. Blood Coagul Fibrinolysis 2016; 27:205-209.
24. Tripodi A, Chantarangkul V, Gianniello F, Clerici M, Lemma L, Padovan L, et al. Global coagulation in myeloproliferative neoplasms. Ann Hematol 2013; 92:1633-1639.
25. Tomori T, Hupalo D, Teranishi K, Michaud S, Hammett M, Freilich D, et al. Evaluation of coagulation stages of haemorrhaged swine: comparison of thromboelastography and rotational elastometry. Blood Coagul Fibrinolysis 2010; 21:20-27.
26. Marchetti M, Castoldi E, Spronk HM, van Oerle R, Balducci D, Barbui T, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 2008; 112:4061-4068.
27. Duchemin J, Ugo V, Ianotto J, Lecucq L, Mercier B, Abrall J. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res 2010; 126:238-242.
28. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103:491-495.
29. Kaifie A, Kirschner M, Wolf D, Maintz C, Hanel M, Gattermann H, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN. J Hematol Oncol 2016; 9:18.
30. Landolfi R, Rocca B, Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatments. Crit Rev Oncol Hematol 1995; 20:203-222.
31. Lippi G, Plebani M, Franchini M, Guidi GC, Favaloro EJ. Prostate-specific antigen, prostate cancer, and disorders of haemostasis. Semin Thromb Hemost 2008; 35:654-664.
32. Kohli M, Kaushal V, Mehta P. Role of coagulation and fibrinolytic system in prostate cancer. Semin Thromb Hemost 2003; 29:301-308.
33. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008; 93:372-380.